🔴 ACADIA Pharmaceuticals is trading 10.6% down today after Alzheimer’s psychosis trial misses primary endpoint

ACADIA Pharmaceuticals is trading 10.6% down at $22.73 after remlifanserin narrowly missed the primary endpoint in the Phase 2 RADIANT Alzheimer’s disease psychosis study.

• The 60-mg dose had a p-value of 0.0603, just above statistical significance.
• A key secondary endpoint showed nominal significance, and Phase 3 enrollment continues.
• Investors appear concerned about the setback to the company’s most important pipeline asset; broader biotech weakness is also adding pressure.